Cite
HARVARD Citation
Gross-Goupil, M. et al. (2018). Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Annals of oncology. pp. 2371-2378. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Gross-Goupil, M. et al. (2018). Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Annals of oncology. pp. 2371-2378. [Online].